Fast forward to Nov 2015, Allergan struck a friendly deal to sell itself to Pfizer $PFE in a tax inversion deal

The all share deal, struck at a 26.6% premium, would allow Pfizer to re-domicile offshore to become "more competitive globally" from a tax perspective

6/